We are live on ! Find out more
LGM

Logos Global Management Portfolio holdings

AUM $2B
1-Year Est. Return 444.09%
This Fund
S&P 500
This Quarter Est. Return
-14.6%
1 Year Est. Return
+444.09%
3 Year Est. Return
+1,593.63%
5 Year Est. Return
+2,146.66%
10 Year Est. Return
–
AUM
$771M
AUM Growth
-$198M
Cap. Flow
-$50.7M
Cap. Flow %
-6.57%
Top 10 Hldgs %
57.03%
Holding
73
New
7
Increased
16
Reduced
17
Closed
26

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$40.3M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$30.7M
3
ARQT icon
Arcutis Biotherapeutics
ARQT
+$21.1M
4
ASND icon
Ascendis Pharma A/S
ASND
+$20.3M
5
IDYA icon
IDEAYA Biosciences
IDYA
+$19.2M

Top Sells

Rank Stock Value
1
ALGS icon
Aligos Therapeutics
ALGS
+$36.9M
2
RPTX
Repare Therapeutics
RPTX
+$35.9M
3
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
+$22.8M
4
ALPN
Alpine Immune Sciences Inc
ALPN
+$15.5M
5
HARP
Harpoon Therapeutics, Inc. Common Stock
HARP
+$14.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DAWN
51
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-37,069
Closed -$624K
ELDN icon
52
Eledon Pharmaceuticals
ELDN
$255M
– –
-1,339,793
Closed -$5.91M
EPIX
53
DELISTED
ESSA Pharma
EPIX
– –
-865,000
Closed -$12.3M
FATE icon
54
Fate Therapeutics
FATE
$275M
– –
-94,000
Closed -$5.5M
FOLD
55
DELISTED
Amicus Therapeutics
FOLD
– –
-625,000
Closed -$7.22M
IVVD icon
56
Invivyd
IVVD
$160M
– –
-70,000
Closed -$508K
JANX icon
57
Janux Therapeutics
JANX
$912M
– –
-185,196
Closed -$3.65M
KYMR icon
58
Kymera Therapeutics
KYMR
$8.66B
– –
-200,000
Closed -$12.7M
MREO
59
Mereo BioPharma
MREO
$48.9M
– –
-46,984
Closed -$75K
PTGX icon
60
Protagonist Therapeutics
PTGX
$8.55B
– –
-250,000
Closed -$8.55M
RLMD icon
61
Relmada Therapeutics
RLMD
$540M
– –
-400,000
Closed -$9.01M
RPTX
62
DELISTED
Repare Therapeutics
RPTX
– –
-1,700,000
Closed -$35.9M
TVTX icon
63
Travere Therapeutics
TVTX
$5.17B
– –
-100,000
Closed -$3.1M
WVE icon
64
Wave Life Sciences
WVE
$1.12B
– –
-800,000
Closed -$2.51M
YMAB
65
DELISTED
Y-mAbs Therapeutics
YMAB
– –
-250,000
Closed -$4.05M
LENZ
66
LENZ Therapeutics
LENZ
$179M
– –
-58,044
Closed -$5.05M
ALPN
67
DELISTED
Alpine Immune Sciences Inc
ALPN
– –
-1,120,000
Closed -$15.5M
MRNS
68
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-130,000
Closed -$1.54M
NGM
69
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
– –
-475,000
Closed -$8.41M
HARP
70
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
– –
-193,000
Closed -$14.6M
LABP
71
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
– –
-137,500
Closed -$6.6M
FMTX
72
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
– –
-1,600,000
Closed -$22.8M
ZGNX
73
DELISTED
Zogenix, Inc.
ZGNX
– –
-350,000
Closed -$5.69M
1 2
3

Similar funds

MYAM
Meiji Yasuda Asset Management Tokyo, Japan $2B AUM 22.52% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
LBC
Lowe Brockenbrough & Co Richmond, Virginia $2.01B AUM 22.05% 1-Year Est. Return
C
Consulta London, United Kingdom $2.01B AUM 16.82% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BGM
Burkehill Global Management New York $2.02B AUM 85.32% 1-Year Est. Return
SC
Syon Capital San Francisco, California $1.99B AUM 22.67% 1-Year Est. Return
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return

Logos Global Management's Q1 2022 Portfolio in Review

As of Q1 2022, Logos Global Management held 73 positions worth $771M, down 20% from $970M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Logos Global Management withdrew a net $50.7M in Q1 2022, closing 26 positions and reducing 17 holdings. Its most notable exit was Aligos Therapeutics, an estimated $36.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, Logos Global Management opened a new position in Neurocrine Biosciences worth $44.5M.

  • Logos Global Management's largest Q1 2022 buy was Neurocrine Biosciences: 475,000 shares worth $44.5M.
  • Logos Global Management added most to Mirati Therapeutics, Inc. Common Stock in Q1 2022, an estimated $30.7M increase.
  • Logos Global Management's biggest Q1 2022 reduction was Verve Therapeutics, cutting an estimated $9.9M.
  • Logos Global Management fully exited Aligos Therapeutics in Q1 2022, selling an estimated $36.9M.
  • Logos Global Management's ten largest holdings make up 57% of its $771M portfolio in Q1 2022.
  • Logos Global Management opened 7 new positions and closed 26 in Q1 2022.
  • Logos Global Management's portfolio value fell 20% quarter-over-quarter to $771M.

Based on Logos Global Management's 13F filing for Q1 2022, filed 16 May 2022.